Journal Scans
Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial
Trastuzumab Extends Survival in Advanced HER2-Positive Gastric Cancer
Y-J Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, F Lordick, A Ohtsu, Y Omuro, T Satoh, G Aprile, E Kulikov, J Hill, M Lehle, J Rüschoff, Y-K Kang, for the ToGA Trial Investigators
20100720
2010 Aug 20
Lancet
Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial
Lancet. 2010 Aug 20;[Epub Ahead of Print], Y-J Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, F Lordick, A Ohtsu, Y Omuro, T Satoh, G Aprile, E Kulikov, J Hill, M Lehle, J Rüschoff, Y-K Kang, for the ToGA Trial Investigators
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. Methods: ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries. Patients with gastric or gastro-oesophageal junction cancer were eligible...
